PeptideOS
← Library

Snap-8

Cosmetic peptide

Also known as: Acetyl Octapeptide-3, Ac-EEMQRRAD-NH2

Tier 4, Documented harm or no usable evidence

Either documented serious adverse events in humans, or effectively no retrievable evidence base. Dosing figures circulating for these compounds have no scientific foundation.

Half-life
Not established · topical

No pharmacokinetic or half-life data exist. Snap-8 is a topical cosmetic ingredient with no established systemic pharmacokinetics in humans or animals. Unlike its close analog Acetyl Hexapeptide-8, no CIR safety assessment and no EU SCCS opinion were located.

Dosing
No established dose

No authoritative value exists, a leave-on formulation ingredient, not a dosed drug. No CIR concentration-of-use survey or SCCS opinion was found, so no sourced maximum use concentration can be reported. Supplier pages claim use at 3-10% of a dilute trade solution and cite ~63% wrinkle-depth reduction in 28 days; these are unverified vendor claims with no peer-reviewed or regulatory source and are not reported here as fact.

Regulatory status
Cosmetic ingredient only. Not an FDA-approved drug and not FDA-reviewed for efficacy. No CIR safety assessment and no EU SCCS opinion were located.
Evidence base
anecdotal · confidence: low
Safety

No regulatory safety assessment was found, so no documented adverse-effect profile can be cited. Absence of documented harm is NOT evidence of safety, reproductive toxicity, genotoxicity, carcinogenicity, and long-term human data all appear to be unavailable. Claims that it acts on the SNARE complex like botulinum toxin are mechanistic marketing claims without clinical confirmation. Topical cosmetic use only; not established for injection or any systemic route. Treat all vendor efficacy and safety claims as unverified.